Articles tagged with Stomach Neoplasms
A new study links H. pylori infection to gastric cancer progression through consistent protein markers, including OLFM4 and ENO1, which stratify patients by cancer risk. The findings provide insights into the biology of infection-induced carcinogenesis and offer potential biomarkers for early detection.
The ESMO Gastrointestinal Cancers Congress 2025 will cover topics such as molecular prevention and precision therapy, patient-centred approaches and quality of life. Key findings include the efficacy and safety of combined immunotherapy for hepatocellular carcinoma and colorectal cancer.
The underwater endoscopic mucosal resection (UEMR) technique demonstrates promising outcomes in the treatment of gastrointestinal neuroendocrine tumors, particularly in rectal tumors. UEMR achieves complete histological resection at a lower cost with minimal requirement for advanced endoscopic skills.
A new study from Brigham and Women's Hospital confirms the use of robotic-assisted resection of gastric GISTs in hard-to-reach locations, ensuring complete tumor removal while preserving organ function. The procedure offers superior visibility and steadier arms, reducing error and damage to surrounding tissue.
A study using data from the Surveillance, Epidemiology, and End Results database found that married individuals had better survival prospects than divorced or widowed people. The researchers developed a nomogram to predict 3-5 year survivals, with marital status being one of several independent prognostic factors.
A proteomic study of 2,002 tumors identified 11 distinct molecular subtypes across 14 tissue-based cancer types, including breast, lung, and brain cancers. These subtypes provide new insights into the deregulated pathways and processes in tumors that make them cancerous.
Researchers at Peking University created a comprehensive single-cell landscape of tumor-infiltrating T cells across 21 cancer types, revealing heterogeneity and dynamics. This study provides an immune-typing scheme that could inform targeted therapy.
The KEYNOTE-811 trial demonstrates a significant improvement in objective response rate (74.4%) and tumor size reduction compared to trastuzumab and chemotherapy. The combination of pembrolizumab, trastuzumab, and chemotherapy markedly reduces tumor size and induces complete responses in some patients.
Researchers identified a protein that interferes with the immune system's response to cancer, allowing tumours to evade killer T-cells. Lower levels of this protein in tumours have been linked to improved survival rates in patients with specific types of cancer, such as liver, head and neck, and stomach cancers.
A new Mayo Clinic research found that tumor mutation burden is significantly inflated in Black patients with cancer compared to White patients, affecting therapy selection. The study suggests that accurate tumor mutational burden is crucial for predicting optimal treatment for patients with diverse ancestral backgrounds.
Researchers at UCM identify low plasma levels of protein TGFB1 and polymorphisms in the gene as biomarkers for poor prognosis in gastric adenocarcinoma. These variants are associated with higher mortality rates and increased risk of developing stomach tumors.
Researchers developed a tumor-penetrating peptide that can deliver chemotherapy drugs deep into pancreatic cancer tumors, increasing effectiveness and reducing metastasis. The therapy showed promising results in animal models, with significant increases in survival and reductions in cancer spread.
Researchers have developed a technology that uses near-infrared hyperspectral imaging (NIR-HSI) along with machine learning to visualize tumors in deep tissue and covered by a mucosal layer. The technique was tested on 12 patients with confirmed cases of gastrointestinal stromal tumors (GISTs), achieving an accuracy of 86% in identifyi...
Researchers have developed a new diagnostic tool that can detect cancer cells in small blood samples and connect them to their original tumor. This method has shown significant correlations between circulating tumor cells and tumor expression levels, allowing for targeted therapeutic agents to be used more accurately.
A research team at HKUMed discovered that exosomes derived from Vδ2-T cells can effectively control EBV-associated tumours and induce T-cell anti-tumour immunity. Allogeneic Vδ2-T-Exos showed higher therapeutic efficacy than autologous Vδ2-T-Exos in humanized mice.
A 1975 discovery about a missing nucleotide in tumor RNA has been linked to cancer development. Researchers have found that the TYW2 gene is epigenetically silenced, causing small but aggressive tumors and leading to poor survival rates.
A recent study published in Genetics found a single genetic mutation in Tasmanian devils that leads to reduced growth of a transmissible cancer. The mutation is also implicated in human prostate and colon cancers, suggesting potential new treatment avenues.
A new radiotracer, 68Ga-DOTA-JR11, has shown excellent imaging performance in detecting liver metastases and providing important information to guide treatment. The study found that 68Ga-DOTA-JR11 performed better than 68Ga-DOTATATE PET/CT in detecting liver lesions, with a higher tumor-to-background ratio.
A systematic overview of viruses in cancer found HPV and EBV in 19 and 5.5 percent of cancer genomes respectively. The study also identified mechanisms by which viruses trigger carcinogenic mutations in DNA.
Researchers developed a new classification system for tumors based on genome sequencing, assigning patients to one of sixteen groups. The system provides important information for diagnosis and treatment, including potential responses to immunotherapy.
Researchers found that tumors with a higher degree of microsatellite instability (MSI) are more likely to respond to immunotherapy. MSI-high tumors have a higher amount of indel mutations, which can generate neoantigens recognized by the immune system.
Researchers from Kanazawa University discovered that genes turned on in response to inflammation are a major cause of gastric cancer. The study found that NOXO1, a component of the NOX1 complex, produces tissue-damaging molecules called reactive oxygen species, leading to mutations in stomach cells and tumor formation.
Researchers have discovered a link between MUC16 gene mutations and higher tumor mutation loads in gastric cancer patients, which may improve response rates to immunotherapy. The study's findings could open up new treatment options for up to 38% of gastric cancer patients.
Researchers discovered that oxygen-starved tumor cells struggle to produce aspartate, a crucial amino acid. By targeting this Achilles' heel, doctors may develop new treatments to block aspartate uptake or production.
Researchers identified a link between ARID1a mutations and mismatch repair deficiency, which can render tumors susceptible to immune checkpoint blockade therapies. The study found that tumors with ARID1a mutations exhibited increased sensitivity to anti-PD-1 therapy, suggesting potential benefits for patients with these mutations.
Researchers at the University of Michigan are developing a pill that makes tumors light up when exposed to infrared light, offering a potential alternative to mammograms. The pill uses a dye that responds to infrared light to tag tumor cells, allowing physicians to better distinguish malignant from benign tumors.
A new clinical trial combines two immunotherapies, PD-1 antibody and poly-IC, to enhance T-cell response against solid tumors. The treatment aims to improve patient outcomes for a wide range of cancers, including lung, liver, colon, and others.
Researchers found that different conditions leading to reduced gastric acid secretion alter the stomach's microbial community, influencing tumor risk. The study suggests that manipulating these bacterial communities may lead to new ways to prevent cancer.
The FLOT4 trial has confirmed the superiority of docetaxel-based triplet therapy over standard care in patients with resectable oesophago-gastric cancer. The treatment improved curative resection rates, progression-free survival, and overall survival.
Recent studies found that tumors exploit neuronal signals to grow and thrive. Researchers aim to develop targeted therapies by interrupting specific molecular pathways co-opted by tumor cells. This growing understanding sheds light on cancer pathology observations.
A study found that AYA patients with small intestine GISTs had improved survival rates compared to older adult patients with stomach GISTs. Surgical management was also associated with improved survival in AYA patients, even those with metastatic cancer.
A recent study has identified more than 2,000 genetic mutations in tissue samples of esophageal tumors, revealing the complexity of cancer cells within individual tumors. The findings demonstrate that different areas of a tumor have unique genetic patterns, making it difficult to target a specific genetic defect.
The new Special Issue addresses topics in epidemiology, basic science, and policy, providing reliable information on digestive cancers in Latin America. Key findings include the rising incidence of gastric cancer and the need for awareness, with five articles from experts in the region.
Researchers have identified new gene fusions and mutations associated with a subset of GIST patients, providing novel insights into the disease's biology. These findings could lead to personalized treatment approaches and improved outcomes for GIST patients.
Researchers found that nerve growth factor and tuft cells stimulate gastric tumor growth through aberrant cholinergic signaling, providing a potential therapeutic target for stomach cancer. Blocking nerve growth factor receptor inhibited stomach cancer growth in mice.
Researchers at IDIBELL have found a common cause of multiple resistance in cancer chemotherapy, highlighting the loss of TP53TG1 molecule as a key driver. This discovery has significant implications for understanding treatment failure and may lead to new therapeutic strategies to overcome chemoresistance.
Researchers at CSI Singapore found that inhibiting protein BMI1 can stop lung cancer growth. Low levels of C/EBPa protein result in poorer survival and high expression of BMI1.
Researchers identify mutation in ATP4a gene responsible for aggressive form of inherited gastric NET. Restoring normal gastric acid balance with hydrogen chloride solution prevents tumour development in genetically engineered mice.
A recent study found that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans in detecting neuroendocrine tumors, leading to improved treatment management and patient outcomes. The imaging method demonstrated no significant toxicity, lower radiation exposure, and increased accuracy.
Researchers at Kazan Federal University and the National Academy of Sciences of Ukraine have identified correlations between superoxide, nitric oxide levels and matrix metalloproteinase activity in gastric cancer patients. This discovery could lead to more accurate diagnostics and personalized treatment plans for stomach cancer.
Researchers at University of California, San Diego School of Medicine found that certain groups of gastrointestinal stromal tumors result in a much higher mortality rate than expected. The study analyzed data from 378 patients with malignant GISTs and discovered significant variability in size and malignant behavior.
PharmaMar's novel Antibody-Drug Conjugate (ADC) MI130004 demonstrates potent anticancer activity against HER2-expressing breast, gastric, and ovarian cancers. The ADC impairs tubulin polymerization, causing mitotic failures and halting cell division in tumor cells.
Researchers have successfully powered micromotors with stomach acid in a living animal, demonstrating their potential for targeted drug delivery and diagnosis of hard-to-reach tumors. The motors achieved remarkable penetration and retention rates, outperforming traditional oral delivery methods.
A new study defines the epidemiology of gastrointestinal stromal tumors (GIST), identifying Asian descent patients as at-risk groups. Patients from this population are 1.5 times more likely to be diagnosed with GIST than others, highlighting a higher incidence rate and survival disparity.
Research at VHIO confirms Myc inhibition as a sound and effective therapeutic strategy for glioma, with no evidence of resistance or side effects. The study reveals new insights into the biology of Myc and its potential to halt normal cell division, leading to tumor cell death.
Researchers identified three distinct molecular classifications of gastric cancer that respond differently to therapies, offering a promising new approach to treatment. The study found that tumors can be grouped into proliferative, metabolic and mesenchymal subtypes, each with unique genomic and epigenomic properties.
Researchers found that TAp73 supports proliferation of human and mouse tumor cells by activating G6PD, increasing PPP activity, and directing glucose to pathways for macromolecule synthesis. This reprogramming allows rapid generation of nucleic acids, lipids, and proteins, enabling tumor cells to thrive.
Researchers have discovered HER2 gene abnormalities in 14 different types of solid tumors, including breast, esophageal, and lung cancers. The study suggests that these irregularities may benefit from existing anti-HER2 therapies, providing new treatment options for patients with advanced cancer.
Individuals who experience an upper gastrointestinal bleed may be more likely to die from other causes, particularly malignant tumours and cardiovascular disease. A study published in PLOS Medicine found that the risk of death due to non-gastrointestinal causes was higher for those with an upper GI bleed.
Researchers at Vall d'Hebron Institute of Oncology have successfully eliminated mouse lung tumors by inhibiting the Myc protein, a key regulator of gene expression and cell growth. The study confirms that Myc-targeted therapy is a safe and effective option for treating various types of cancer, with no signs of resistance or side effects.
A new formulation of cisplatin has been developed to improve the effectiveness and safety of cancer treatment. The pH-sensitive liposome was able to reduce cancer cell proliferation and increase survival in animal models with no known toxicity clinical signs.
Patients with high-risk GI tumors who received imatinib for 3 years instead of 1 year had improved recurrence-free survival and overall survival. The study found that longer treatment with the cancer drug resulted in better survival outcomes and fewer patients discontinued treatment due to adverse effects.
Researchers at the University of Georgia have made a breakthrough in pig-induced pluripotent stem cells, showing they can safely incorporate into tissues without tumor formation. This finding has significant implications for stem cell therapies and potentially reduces the need for rodent-based models.
Researchers developed a mouse model to track bone marrow cell migration to tumors and found that these cells can slow tumor growth. The study suggests that targeting bone marrow cells may lead to more effective cancer treatments.
Researchers found FSH receptor present in all cancer tumour samples, regardless of type or stage. The discovery highlights the potential of this receptor as a target for anti-cancer drugs and imaging procedures.
Researchers found that bacteria can selectively target and kill cancer cells in tumors of a specific medium size, leading to complete tumor disappearance. The therapy works by germinating and growing bacterial spores in the oxygen-free tumor centers, causing damage to surrounding tumor cells.
Researchers found that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, than those who respond least. The study suggests that identifying molecular factors associated with a major pathologic response could lead to important progress in t...
The study found that overexpressing ARD1A reduces primary tumors and metastases by blocking VEGFA expression. ARD1A's effect on tumor growth was confirmed through reduced microvessel density.
The study evaluated EUS features to distinguish GISTs from leiomyomas and found that inhomogenicity, hyperechogenic spots, a marginal halo, and higher echogenicity were more frequent in GISTs. The presence of at least two of these four features had high sensitivity (89.1%) and specificity (85.7%) for predicting GISTs. A maximal diamete...
Patients with gastrointestinal stromal tumor (GIST) who received adjuvant imatinib after surgery experienced increased recurrence-free survival compared to those given placebo. Imatinib significantly improved recurrence-free survival at one year, with the most impact on tumors over 10cm in size.